Ab­b­Vie en­lists pro­tein degra­da­tion ex­perts at Mis­sion for a new bet on Alzheimer's, Parkin­son's

As a group of pre­clin­i­cal biotechs fo­cused on pro­tein degra­da­tion steadi­ly gath­ers steam, Ab­b­Vie is jump­ing on the band­wag­on al­beit steer­ing it to a some­what sur­pris­ing di­rec­tion: Alzheimer’s and Parkin­son’s dis­eases.

Mis­sion Ther­a­peu­tics, its cho­sen part­ner, has been con­cen­trat­ing much of its ef­forts on hit­ting USP30 and USP10 — two of over 100 deu­biq­ui­ty­lat­ing en­zymes, or DUBs, in the hu­man body that col­lec­tive­ly serve as a nat­ur­al “garbage dis­pos­al” sys­tem for cells — with one USP30 pro­gram in Parkin­son’s and neu­rode­gen­er­a­tion. Ab­b­Vie, though, is more in­ter­est­ed in iden­ti­fy­ing new DUB tar­gets and get­ting Mis­sion’s dis­cov­ery plat­form to churn out be­spoke com­pounds.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER